Drug intelligence / Profile preview

Butacaine

Development stage: Unknown
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

Butacaine is a white crystalline ester used as a local anesthetic. It acts primarily by blocking sodium channels in nerve membranes, thereby inhibiting nerve impulse conduction and producing local anesthesia. First marketed in 1920, it is an ester-type anesthetic chemically classified as a benzoate ester. It should not be used in individuals with known allergies to local anesthetics due to the risk of anaphylactic shock[3][5][7].

Brand names: ButellineButyn
Other names: butacaineButacainaButacainum3-(Dibutylamino)propyl 4-aminobenzoatebutacaine sulfate

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)Mitochondrial proton transport machineryKCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)

Beyond the preview

Go deeper on Butacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Butacaine.

Explore the full profile